Supriya Mallick1, Rony Benson, P K Julka, G K Rath. 1. Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India, drsupriyamallick@gmail.com.
Abstract
BACKGROUND: Anal canal is the lower most part of the gastrointestinal tract harbouring 4 % of all gastrointestinal cancer. Most common treatment for anal canal carcinoma includes chemoradiotherapy. METHODOLOGY: We reviewed the recent landmark trials to find a road map in the management of anal canal carcinoma. RESULTS: Concurrent chemoradiotherapy appears to be the most effective treatment schedule. Induction, as well as maintenance chemotherapy, has no definite role. Moderate dose radiation 50.4-54 Gy with concurrent mitomycin C (MMC) and 5-fluorouracil (5-FU) remains the standard. Split course is detrimental. Intensity-modulated radiotherapy and targeted drugs are investigated. CONCLUSION: Combined modality therapy is the standard for anal canal carcinoma.
BACKGROUND: Anal canal is the lower most part of the gastrointestinal tract harbouring 4 % of all gastrointestinal cancer. Most common treatment for anal canal carcinoma includes chemoradiotherapy. METHODOLOGY: We reviewed the recent landmark trials to find a road map in the management of anal canal carcinoma. RESULTS: Concurrent chemoradiotherapy appears to be the most effective treatment schedule. Induction, as well as maintenance chemotherapy, has no definite role. Moderate dose radiation 50.4-54 Gy with concurrent mitomycin C (MMC) and 5-fluorouracil (5-FU) remains the standard. Split course is detrimental. Intensity-modulated radiotherapy and targeted drugs are investigated. CONCLUSION: Combined modality therapy is the standard for anal canal carcinoma.
Authors: H Bartelink; F Roelofsen; F Eschwege; P Rougier; J F Bosset; D G Gonzalez; D Peiffert; M van Glabbeke; M Pierart Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: Michael Papagikos; Christopher H Crane; John Skibber; Nora A Janjan; Barry Feig; Miguel A Rodriguez-Bigas; Arthur Hung; Robert A Wolff; Marc Delclos; Edward Lin; Karen Cleary Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-01 Impact factor: 7.038
Authors: J Northover; R Glynne-Jones; D Sebag-Montefiore; R James; H Meadows; S Wan; M Jitlal; J Ledermann Journal: Br J Cancer Date: 2010-03-16 Impact factor: 7.640
Authors: Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett Journal: J Clin Oncol Date: 2012-11-13 Impact factor: 44.544
Authors: A Allal; J M Kurtz; G Pipard; M C Marti; R Miralbell; Y Popowski; R Egeli Journal: Int J Radiat Oncol Biol Phys Date: 1993-09-01 Impact factor: 7.038
Authors: Andre Konski; Miguel Garcia; Madhu John; Richard Krieg; Wayne Pinover; Robert Myerson; Christopher Willett Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-09 Impact factor: 7.038
Authors: Timothy M Pawlik; Ana Luiza Gleisner; Todd W Bauer; Reid B Adams; Srinevas K Reddy; Bryan M Clary; Robert C Martin; Charles R Scoggins; Kenneth K Tanabe; James S Michaelson; David A Kooby; Charles A Staley; Richard D Schulick; Jean-Nicolas Vauthey; Eddie K Abdalla; Steven A Curley; Michael A Choti; Dominque Elias Journal: Ann Surg Oncol Date: 2007-06-06 Impact factor: 5.344